Physician profile
Joseph Kappil
NPI 1659423622
$1,936.13
in general payments reported to CMS, 2019-2025
19 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $108 · 2021: $213 · 2022: $249 · 2023: $287 · 2024: $437 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $259.44 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $220.66 | 2019-2023 | |
| Oyster Point Pharma, INC. | $212.29 | 2022-2024 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $197.96 | 2022-2025 | Rocklatan, Tryptyr, Hydrus Microstent |
| Allergan, INC. | $151.00 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $150.27 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $122.15 | 2023-2025 | Miebo, Xiidra, Lotemax Sm |
| Aerie Pharmaceuticals, INC. | $102.84 | 2019-2021 | |
| Sight Sciences, INC. | $96.79 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| New World Medical,INC. | $90.46 | 2025 | Clearpath, Via360, Streamline |
| Thea Pharma INC. | $64.97 | 2022-2024 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $60.47 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $56.76 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $48.68 | 2021-2024 | Oxervate |
| Harrow Eye, LLC | $30.56 | 2024 | Vevye |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.28 | 2024 | Izervay |
| Glaukos Corporation | $17.85 | 2019 | |
| Biotissue Holdings INC. | $17.09 | 2021 | |
| Shire North American Group INC | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Kappil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.